Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Triptorelin GnRHExplore study findings

The prostate cancer trial that holds triptorelin constant

2 numbered sourcesSource years 2026

Peptides are short chains of amino acids joined by peptide bonds. Some act like hormones, delivering a message when they bind a receptor. Triptorelin is a synthetic ten-amino-acid version of gonadotropin-releasing hormone, or GnRH. With sustained exposure it lowers testosterone, and the U.S. prescribing label for Trelstar identifies advanced prostate cancer as its approved use. A 2026 study plan in metastatic prostate cancer asks whether adding surgery changes outcomes when participants in both groups continue receiving triptorelin and another cancer drug. [1, 2]

The protocol calls for initial treatment with triptorelin, the chemotherapy drug docetaxel, and the androgen receptor pathway inhibitor rezvilutamide. The researchers intend to randomly assign 88 eligible patients after initial therapy. Candidates must meet a low prostate-specific antigen (PSA) criterion and be considered suitable for surgery. Both groups will continue triptorelin and rezvilutamide. The experimental group will also have robot-assisted surgery to remove the prostate and reduce the amount of tumor tissue at the original site. [1]

The researchers will compare how long patients live without documented progression and the proportion without progression at one year. They plan to identify progression using changes in PSA, imaging, or clear clinical changes. Overall survival and health-related quality of life are separate secondary outcomes. Those distinctions matter because a change in PSA, a protein measured in blood, and a change in daily life or overall survival answer different questions. [1]

Keeping the systemic medicines the same after randomization lets the comparison focus on the added surgery. It also means any group difference would be interpreted in the context of that common treatment and the patients selected after initial therapy. The 2026 publication describes how the investigators will answer the question. It reports a protocol, with benefit and harms from the added surgery still to be measured. [1]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop Triptorelin GnRH

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.